|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on January 2, 2003; DOI 10.1182/blood-2002-09-2712.
IMMUNOBIOLOGY
From the Department of Immunology and Medical Zoology,
Division of Human Retroviruses, Center for Chronic Viral Diseases,
School of Medicine, Kagoshima University, Kagoshima City, Kagoshima,
Japan; and the Department of Advanced Medical Science, The
Institute of Medical Science, University of Tokyo,
Japan.
To exploit a novel strategy to regulate T cell-mediated immunity,
we established human and murine modified dendritic cells (DCs) with
potent immunoregulatory properties (designed as regulatory DCs), which
displayed moderately high expression levels of major histocompatibility
complex (MHC) molecules and extremely low levels of costimulatory
molecules compared with their normal counterparts. Unlike human normal
DCs, which caused the activation of allogeneic CD4+ and
CD8+ T cells, human regulatory DCs not only induced their
anergic state but also generated CD4+ or CD8+
regulatory T (Tr) cells from their respective naive subsets in vitro. Although murine normal DCs activated human xenoreactive T cells
in vitro, murine regulatory DCs induced their hyporesponsiveness. Furthermore, transplantation of the primed human T cells
with murine normal DCs into severe combined immunodeficient (SCID) mice
enhanced the lethality caused by xenogeneic graft-versus-host disease
(XGVHD), whereas transplantation of the primed human T cells with
murine regulatory DCs impaired their ability to cause XGVHD. In
addition, a single injection of murine regulatory DCs following
xenogeneic or allogeneic transplantation protected the recipients from
the lethality caused by XGVHD as well as allogeneic acute GVHD. Thus,
the modulation of T cell-mediated immunity by regulatory DCs provides
a novel therapeutic approach for immunopathogenic diseases.
(Blood. 2003;101:3581-3589) Dendritic cells (DCs) are unique professional major
antigen (Ag)-presenting cells (APCs) capable of stimulating naive T
cells in the primary immune response and are more potent APCs than
monocytes/macrophages or B cells.1
The treatment of normal immature DCs (iDCs) with interleukin 10 (IL-10) caused a down-regulation in the expressions of major histocompatibility complex (MHC) and costimulatory molecules, leading
to a suppression of their T cell-stimulatory ability2 as
well as an induction of anergic T cells.3,4 Recently, repetitive stimulation of human naive CD4+ T cells with
allogeneic normal iDCs not only induced T-cell anergy but also
generated CD4+CD25+CD152+
regulatory T (Tr) cells from their naive subsets.5
Furthermore, a single injection of antigenic peptide-pulsed normal iDCs
led to an appearance of Ag-specific IL-10-producing CD8+ T
cells in healthy individuals.6 However, the clinical
application of self Ag-pulsed or allogeneic/xenogeneic normal iDCs may
not be suitable for the treatment of autoimmune diseases or for
allogeneic/xenogeneic organ transplantation because the injected normal
iDCs are not likely to remain immature in vivo after recirculation and
home into the damaged tissue where chronic inflammation is always
present.7 Therefore, further development of DCs with
potent negative regulatory ability for T cells is thought to facilitate
their use for the prevention and the treatment of immunopathogenic diseases.
To exploit a novel strategy involving the use of DCs for the regulation
of T cell-mediated immunity, we examined the effect of human and
murine modified DCs with potent immunoregulatory properties (designed
as regulatory DCs) on allogeneic/xenogeneic T-cell responses in vivo
and in vitro.
Mice, media, and reagents
Cell preparations
The generation of murine normal DCs was performed according to
the previous report8 with some modifications. Briefly,
bone marrow (BM) cells (BALB/c mice) were cultured with murine GM-CSF (20 ng/mL) in a bacteriologic Petri dish (BIO-BIK, Tokyo, Japan) for 6 days. Nonadherent cells were collected and subjected to the negative
selection with mAbs to Ly-76, CD2, B220, CD14, and Ly-6G (all from BD
Pharmingen) plus sheep antirat IgG mAb-conjugated immunomagnetic beads
(Dynal). The resultant cells were washed 3 times with cold PBS after
the generation to prevent carryover of cytokines and stimulated with
lipopolysaccharide (1 µg/mL; Sigma) in a bacteriologic Petri dish for
2 days. Similarly, murine modified/regulatory DCs were also obtained by
culturing BM cells with murine GM-CSF (20 ng/mL), murine IL-10 (20 ng/mL), and human TGF- Human skin fibroblasts were prepared from epidermal skin tissues after obtaining informed consent from 2 different healthy volunteers. Human total T cells were purified from PBMCs obtained from 20 healthy volunteers with a T-cell negative isolation kit (Dynal).9 Subsequently, naive CD4+ or CD8+ T cells were negatively selected from total T cells with anti-CD8 mAb or anti-CD4 mAb (each from BD Pharmingen) in combination with anti-CD45RO mAb (BD Pharmingen) plus goat antimouse IgG mAb-conjugated immunomagnetic beads (Dynal). These T-cell preparations were typically more than 98% pure as indicated by FACS analysis. For preparation of human Ag-specific CD8+ T cells, PBMCs were cocultured with irradiated (15 Gy from a 137Cs source, MBR-1505R2, Hitachi Medical, Tokyo, Japan) allogeneic fibroblasts derived from an unrelated donor (donor no. 1) in the presence of human IL-2 (100 U/mL) for 2 weeks,4 and CD8+ T cells were positively selected with a CD8+ isolation kit (Dynal) from the coculture. Flow cytometry Cells were stained with the following mAbs to human and murine markers: CD1a and CD83 (Coulter Immunology, Hialeah, FL); CD3, CD11c, CD25, CD28, CD40, CD45, CD80, CD86, CD152, CD154, HLA-A/B/C, I-Kd, and isotype-matched control mAb (all from BD Pharmingen); and anti-E-cadherin (E-cad) mAb (Chemicon International, Temecula, CA).2,4 For analysis of the intracellular expression of cytokines,4 permeabilized/fixed cells were stained with mAbs to human IL-2, IL-4, IL-10, and interferon (IFN-; all from BD Pharmingen) following stimulation with
plate-bound antihuman CD3 mAb (10 µg/mL; BD Pharmingen) plus soluble
antihuman CD28 mAb (10 µg/mL; BD Pharmingen; for CD4+ T
cells) or phorbol myristate acetate (PMA; 20 ng/mL; Sigma) plus
Ca2+ ionophore A23187 (500 ng/mL; Sigma; for
CD8+ T cells) for 6 hours. Fluorescence staining was
analyzed with a FACScan flow cytometer and CellQuest software (Becton
Dickinson, Mountain View, CA), and data are expressed as mean
fluorescence intensity (MFI).
Allogeneic/xenogeneic priming of human T cells in vitro Human naive CD4+ T cells or Ag-specific CD8+ T cells (5 × 106) were primed with irradiated (15 Gy) human allogeneic DCs (5 × 103 to 5 × 105) for 3 days, and these T-cell subsets were negatively selected with antihuman CD11c mAb (BD Pharmingen) plus goat antimouse IgG mAb-conjugated immunomagnetic beads. These T-cell preparations contained less than 0.1% CD11c+ cells as assessed by FACS analysis. For in vitro xenogeneic priming, human T cells (5 × 107) were primed with irradiated (15 Gy) murine DCs (5 × 106, H-2d) in the presence or absence of human IL-2 (100 U/mL) for 3 days. After incubation, human T cells were negatively selected with anti-I-Kd mAb (BD Pharmingen) plus goat antimouse IgG mAb-conjugated immunomagnetic beads. These T-cell preparations contained less than 0.1% I-Kd+ cells as assessed by FACS analysis. Cells were rested in medium containing human IL-2 (10 U/mL) for 3 days before use.Mixed leukocyte reaction Human T-cell subsets (105) were cultured in 96-well plates (Costar, Cambridge, MA) with various numbers of irradiated (15 Gy) allogeneic/xenogeneic DCs in the presence or absence of human IL-2 (100 U/mL). Thymidine incorporation was measured as counts per minute (cpm) for the indicated days after an 18-hour pulse with [3 H]-thymidine.2,4Cytotoxic T-lymphocyte assay Ag-specific CD8+ T cells (5 × 105) were cultured with Na Preparation of Tr-cell subsets Human CD4+CD45RA+ T cells (5 × 106) were cultured with irradiated (15 Gy) allogeneic normal mDCs (5 × 105) for 3 days, and Ag-primed CD4+ T cells were obtained from the coculture by the depletion of DCs as described in "Allogeneic/xenogeneic priming of human T cells in vitro." Human CD4+CD45RA+ T cells (5 × 106) were also cultured with irradiated (15 Gy) allogeneic regulatory iDCs (5 × 105) for 5 days, and T cells were negatively selected by the depletion of DCs. CD4+CD25+ T cells or CD4+CD25 T cells were then selected
with anti-CD25 mAb (BD Pharmingen) plus goat antimouse IgG
mAb-conjugated immunomagnetic beads, and they were typically more than
95% pure as indicated by FACS analysis.
Human naive CD8+ T cells (5 × 106) were
cocultured with allogeneic normal mDCs (5 × 105) or
regulatory iDCs (5 × 105) for 5 days, and
CD8+ T cells were negatively selected by the depletion of
DCs. Subsequently, CD8+CD28+ T cells or
CD8+CD28 The removal of the immunomagnetic beads from the selected cells was performed by competitive detachment with mouse serum for 4 hours, and they rested in medium for 16 hours according to the manufacturer's instruction manual. After incubation, the residual immunomagnetic beads were removed by the magnetic particle concentrator (MPC-S, Dynal). Analysis of Tr-cell function Ag-primed CD4+ T cells or CD4+CD25+ T cells (105) were cultured with irradiated (15 Gy) allogeneic normal mDCs (104) in the presence or absence of different numbers of CD4+CD25+ T cells or Ag-primed CD4+ T cells in 96-well plates. In another experiment, Ag-primed CD4+ T cells (105) were cultured with irradiated (15 Gy) allogeneic normal mDCs (104) in the presence or absence of different numbers of CD8+CD28+ T cells or CD8+CD28 T cells in 96-well plates. The
proliferative response of T cells was evaluated on day 5 by
[3H]-thymidine incorporation. Alternatively, human
CD8+CD28+ T cells or
CD8+CD28 T cells (106) plus
irradiated (15 Gy) allogeneic normal mDCs (105) were either
added directly to the coculture of Ag-primed CD4+ T cells
(106) with irradiated (15 Gy) allogeneic normal mDCs
(105) in 24-well plates (Costar) or were placed separately
in 24-well Transwell cell culture chambers (Millicell, 0.4-µm pore
size; Millipore, Bedford, MA) in the same well for 4 days. Following depletion of DCs, total T cells (105/well) were transferred
to 96-well plates. The proliferative response was measured after an
additional 18-hour pulse with [3H]-thymidine.
A model of XGVHD in SCID mice engrafted with human peripheral blood lymphocytes and murine allogeneic acute GVHD For xenogeneic transplantation, SCID mice (5 animals in each group) were pretreated 1 day prior to the transplantation with a single dose (lyophilized Ab was resuspended in 1 mL PBS, and 20 µL/mouse was given by intraperitoneal injection) of anti-asialo GM1 antiserum (the protein concentration was 10 mg/mL, WAKO, Osaka, Japan).10 Immediately prior to the transplantation, SCID mice were exposed to a sublethal total body irradiation (5 Gy/mouse).10 Subsequently, unprimed human T cells or xenogeneic primed human T cells prepared as described (4 × 107/mouse) were intravenously injected into SCID mice under sterile conditions. For murine allogeneic transplantation, SCID mice received a lethal total body irradiation (10 Gy/mouse), and the recipients were injected with BM cells (H-2b, 2 × 107/mouse) plus spleen mononuclear cells (H-2b, 2 × 107/mouse). In a parallel experiment, SCID mice engrafted with human peripheral blood lymphocytes (hu-PBL-SCID mice; 5 animals in each group) or SCID mice underwent allogeneic transplantation (5 animals in each group), receiving a single intravenous injection of murine normal or modified/regulatory DCs (4 × 106/mouse) 2 days after allogeneic/xenogeneic transplantation. Alternatively, intravenous injections of human IL-2 (104 U/mouse) were performed on days 3, 5, and 7 after xenogeneic transplantation in hu-PBL-SCID mice receiving murine modified/regulatory DCs (5 animals in each group). Recipients were monitored once every day from the day of transplantation until they died naturally of xenogeneic graft-versus-host disease (XGVHD), and the survival (%) was calculated as a function of time. In another experiment, hu-PBL-SCID mice (5 animals in each group) were killed on day 10 after xenogeneic transplantation to obtain spleen tissue. Spleen mononuclear cells were obtained by centrifugation with the use of Histopaque-1080 (Sigma), and the interphase fraction was recovered. The engraftment of human T cells in spleen in hu-PBL-SCID mice was then accessed by FACS analysis with mAbs to human CD3 and CD45. Transplanted human T cells were also negatively selected from spleen mononuclear cells with anti-I-Kd mAb plus goat antimouse IgG mAb-conjugated immunomagnetic beads. Cells were rested in medium containing human IL-2 (10 U/mL) before use.Statistical analysis Data are expressed as mean values ± SD of all individual experiments. All analyses for statistically significant differences were performed with the Student paired t test or Mann-Whitney U test. P < .01 was considered significant.
Human modified DCs act as regulatory DCs to induce T-cell anergy Modified iDCs expressed both the DC-marker (CD1a and CD11c) and the Langerhans cell marker (E-cad), but not the monocyte/macrophage-marker (CD14) as shown in Figure 1A. On the other hand, they showed moderately high expression levels of MHC molecules (HLA-A/B/C and HLA-DR), whereas they exhibited extremely low levels of costimulatory molecules (CD40, CD80, and CD86) as compared with normal iDCs (Figure 1B-D). On stimulation with TNF- , CD83 was detected, whereas the DC
and the Langerhans cell markers were down-regulated (Figure 1A). In addition, the expression levels of MHC and costimulatory molecules were
changed to various degrees following this stimulation (Figure 1B-D). We
also observed that modified DCs were less effective for the activation
of allogeneic CD4+ T cells than normal DCs and
IL-10-treated iDCs (Figure 2A-B).
We examined the ability of allogeneic modified DCs to induce T-cell
anergy. The primed naive CD4+ T cells with allogeneic
normal DCs showed vigorous response to the same donor-derived normal
mDCs (Figure 2A). In contrast, the primed naive CD4+ T
cells with allogeneic-modified DCs were hyporesponsive to further stimulation with the same donor-derived normal mDCs, and the addition of IL-2 to a second culture partly enhanced this response (Figure 2A).
Similar results were observed when total CD4+ T cells were
used as the responder cells, and the degree of modified DC-induced
T-cell hyporesponsiveness was higher than that of IL-10-treated iDCs
(Figure 2B).
Furthermore, allogeneic modified DCs induced anergic CD4+ T cells in a dose-dependent manner (Figure 2C), and they retained the hyporesponsiveness at least for 2 weeks (Figure 2D). In addition, the primed CD4+ T cells with allogeneic-modified DCs exhibited a weaker response to the unrelated donor-derived allogeneic normal mDCs in a second culture than those primed with allogeneic normal DCs (Figure 2A). We also examined the effect of modified DCs on allogeneic normal mDC-mediated activation of allogeneic CD4+ T cells (Figure 2E). The addition of allogeneic normal mDCs, but not normal iDCs, to the coculture of Ag-primed CD4+ T cells with normal mDCs slightly enhanced their response, whereas allogeneic-modified DCs significantly suppressed this response in a dose-dependent manner. We further tested the effect of allogeneic-modified DCs on cytotoxic T-lymphocyte (CTL) activity of Ag-specific CD8+ T cells (Figures 2F). These CD8+ T cells showed cytotoxicity only against allogeneic fibroblasts (donor no. 1) used in their generation, indicating that their cytotoxicity was Ag specific. Stimulation with allogeneic normal mDCs, but not normal iDCs, enhanced their CTL activity, whereas treatment with allogeneic-modified DCs suppressed it in a dose-dependent manner. Furthermore, little or no change in CTL activity was observed when they were treated with allogeneic DCs derived from unrelated donor (donor no. 2) to allogeneic fibroblasts used in their generation, indicating that their regulations were Ag specific. Similar results were observed in other allogeneic combinations (data not shown). Collectively, human modified DCs were potent regulators for alloreactive effector T cells, and we referred to modified DCs as regulatory DCs. Human regulatory DCs induce CD4+CD25+ Tr cells CD4+CD25+ T cells reportedly act as Tr cells to suppress the responses of alloreactive or self-reactive CD4+ T cells in an Ag-nonspecific manner, and this T-cell subpopulation is supposed to maintain immunologic self-tolerance or control autoimmunity.11-13 A single stimulation with allogeneic regulatory DCs predominantly generated CD4+CD25+ and CD4+CD152+ T cells from naive CD4+ T cells, whereas allogeneic normal DCs induced CD4+CD25+ and CD4+CD154+ T cells (Figure 3A). We also observed that a large proportion of CD4+CD25+ T cells expressed CD152 (data not shown). On the other hand, IL-10-producing CD4+ T cells were increased in the primed CD4+ T cells with allogeneic regulatory DCs, whereas IFN-- and IL-2-producing CD4+ T cells were increased in the primed CD4+
T cells with allogeneic normal DCs as compared with unprimed CD4+ T cells (Figure 3B).
To examine the function of CD4+CD25+ T cells
generated from the primed naive CD4+ T cells with
allogeneic regulatory iDCs, we examined their effect on allogeneic
normal mDC-induced activation of Ag-primed CD4+ T cells
(Figure 3C). Ag-primed CD4+ T cells vigorously responded to
allogeneic normal mDCs, whereas CD4+CD25+ T
cells exhibited a poor response. In addition,
CD4+CD25+ T cells suppressed the response of
Ag-primed CD4+ T cells to allogeneic normal mDCs in a
dose-dependent manner. However, we did not observe a dose-response
relationship in which Ag-primed CD4+ T cells overcame the
suppressive effect of CD4+CD25+ T cells when
CD4+CD25+ T cells were cultured with allogeneic
normal mDCs in the presence of increasing numbers of Ag-primed
CD4+ T cells, indicating that this suppressive effect may
not be due to their simple competition for allogeneic normal mDCs. We
also observed that the separation of CD4+CD25+
T cells and Ag-primed CD4+ T cells abolished their
inhibitory effect, and the addition of IL-2 restored the response of
Ag-primed CD4+ T cells at least partially, whereas
neutralizing Abs against IL-10 or TGF- Human regulatory DCs induce CD8+CD28 -producing CD8+CD28 Tr cells
regulating the response of CD4+ T cells.14-16
On the other hand, a single injection of antigenic peptide-pulsed
normal iDCs into humans induced peptide-specific CD8+ T
cells producing IL-10.6 The coculture of naive
CD8+ T cells with allogeneic regulatory DCs induced
CD8+ CD28 T cells, whereas allogeneic normal
DCs preferentially generated CD8+CD28+ T cells
(Figure 4A). In addition,
IL-10-producing CD8+ T cells were increased in the primed
CD8+ T cells with allogeneic regulatory DCs, whereas
IFN--producing CD8+ T cells were increased in the
primed CD8+ T cells with allogeneic normal mDCs as compared
with unprimed CD8+ T cells (Figure 4A).
We also examined the effect of CD8+CD28 Impairment of xenogeneic response of human T cells by murine regulatory DCs There is increasing interest in xenogeneic organ transplantation in a clinical setting, and the suppression of human xenoreactive T cells is thought to be crucial for xenogeneic organ transplantation. To test whether regulatory DCs can regulate xenoreactive T cells, we generated modified DCs from murine BM cells (H-2d). In contrast to murine normal DCs, murine modified DCs showed moderately high expression levels of the DC marker (CD11c) and MHC molecules (I-Kd and I-A/I-E), whereas they exhibited extremely low levels of costimulatory molecules (CD40, CD80, CD86; Figure 5A). Furthermore, murine modified DCs showed poor activation of human T cells as compared with murine normal DCs (data not shown). In addition, the primed human T cells with murine normal DCs (H-2d) responded to restimulation with murine normal mDCs (H-2d), whereas the primed human T cells with murine modified DCs failed to respond to this stimulation (data not shown), indicating that murine modified DCs also act as regulatory DCs to induce an anergy in human xenoreactive T cells.
The preventive effect of a group of DCs on T cell-mediated immunopathogenic diseases via an induction of T-cell anergy remains unknown. The hu-PBL-SCID mice (H-2d) reportedly showed a lethal XGVHD, and the depletion of human CD4+ T cells abrogated this pathogenesis.10 To evaluate the inhibitory effect of regulatory DCs on T cell-mediated immunopathogenesis in vivo, we examined the ability of the primed human T cells with murine regulatory DCs to induce XGVHD in hu-PBL-SCID mice (Figure 5B). All hu-PBL-SCID mice (control group) died of XGVHD within 24 days following transplantation. In these mice, clinical symptoms of XGVHD, such as hair ruffling, lower mobility, and weight loss became apparent within 15 days. Transplantation with the primed human T cells with murine normal DCs enhanced the incidence of XGVHD, and this treatment reduced the life span of these engrafted mice as compared with the control group (P < .01). In contrast, the incidence of XGVHD was significantly reduced in SCID mice receiving transplants of the primed human T cells with murine regulatory DCs compared with the control group (P < .01). In addition, the survival period was significantly reduced when SCID mice received transplants of the primed human T cells with murine regulatory DCs in the presence of human IL-2 (P < .01). We also examined the xenogeneic response of the transplanted human T cells obtained from the spleen in hu-PBL-SCID mice 10 days following xenogeneic transplantation against murine normal DCs (H-2d; Figure 5C). Analysis of the spleen in each group of hu-PBL-SCID mice showed that they were consistently engrafted with approximately 80% of human T cells at 10 days after xenogeneic transplantation. The xenogeneic response of the transplanted human T cells obtained from SCID mice receiving transplants of the primed human T cells with murine normal DCs was higher than that of human T cells obtained from hu-PBL-SCID mice. In contrast, the transplanted human T cells obtained from SCID mice transplanted with the primed human T cells with murine regulatory DCs had a poor xenogeneic response to murine normal DCs. We further examined the therapeutic effect of a single injection with murine regulatory DCs following xenogeneic transplantation on the lethality caused by XGVHD in hu-PBL-SCID mice (Figure 5D). A single injection with murine regulatory DCs (4 × 106/mouse) following xenogeneic transplantation had no effect on the engraftment of human T cells in spleen in hu-PBL-SCID mice. Interestingly, this injection prolonged the life span of hu-PBL-SCID mice compared with the control group (P < .01), whereas a single injection of the lower dose (< 4 × 105/mouse) of murine regulatory DCs failed to exhibit a significant therapeutic effect (data not shown). We also observed that the sequential injections of human IL-2 abrogated their therapeutic effect. Similarly, a single injection with murine regulatory DCs (4 × 106/mouse), but not murine normal DCs (4 × 106/mouse), following allogeneic transplantation showed a therapeutic effect on the lethality caused by allogeneic acute GVHD (Figure 5E).
Although DCs reportedly act as natural adjuvants to induce protective immunity against cancer and infectious diseases in humans, the strategy of the DC-mediated negative regulation of the T-cell response has not been established. To the best of our knowledge, this is the first paper to report that a group of human and murine DCs retain the potent immunoregulatory property in vitro and in vivo even under inflammatory conditions and show a protective effect on immunopathogenic disease. We showed that the inflammatory stimulation failed to elicit a fully immunostimulatory maturational change in human regulatory iDCs, whereas the maturation-associated change in several cell surface molecules was observed. Therefore, the maturational process may be selectively impaired in human regulatory DCs. Analysis of phenotype and function of normal DCs suggest that they
could efficiently deliver potent signals to T-cell receptor for Ag
(TCR) ligands (signal 1) and to costimulatory molecules (signal
2)1,17 in alloreactive CD4+ T cells. In
contrast, IL-10-treated iDCs3,4 and
1 We showed that priming with allogeneic normal mDCs enhanced the cytolytic activity of Ag-specific CD8+ T cells in an Ag-dependent manner. Therefore, allogeneic normal mDCs may activate these CD8+ T cells mediated through the delivery of potent signal 1 plus signal 2. On the other hand, the primed allogeneic Ag-specific CD8+ T cells with allogeneic regulatory DCs had reduced their activity in an Ag-dependent manner. Our results suggest that regulatory DCs deliver potent signal 1 plus poor signal 2 to Ag-specific CD8+ T cells, and that results in the induction of their anergic state. Serial stimulations were needed for allogeneic normal iDCs to induce CD4+CD25+ Tr cells from naive CD4+ T cells.5 On the other hand, we have recently reported that a single stimulation with IL-10-induced semimature DCs could induce CD4+CD25+ Tr cells from the unprimed CD4+ T cells.4 We showed that a single stimulation with allogeneic regulatory DCs was sufficient for the efficient generation of CD4+CD25+ Tr cells from naive CD4+ T cells, indicating that regulatory DCs had a much more potent ability to induce CD4+CD25+ Tr cells as compared with normal iDCs and IL-10-induced semimature DCs. On the other hand, the mechanism responsible for the generation of CD4+ CD25+ Tr cells from the primed naive CD4+ T cells with allogeneic regulatory DCs remains unknown. Our results imply that allogeneic regulatory DCs may convert naive CD4+ T cells into CD4+CD25+ Tr cells. However, we cannot exclude the possibility that minimal numbers of CD4+CD25+ T cells were included in cocultures. It is possible that allogeneic regulatory DCs may preferentially expand naturally existing CD4+CD25+ T cells. Further study will be needed to test these possibilities. The allogeneic regulatory DC-induced anergic state in CD4+ T cells was partly restored by IL-2. CD4+CD25+ Tr cells were reportedly unresponsive to IL-2.19 Thus, this mechanism may involve the existence of CD4+CD25+ Tr cells. On the other hand, allogeneic regulatory DC-induced CD4+CD25+ Tr cells caused the allogeneic Ag-specific and -nonspecific inhibitory effects. CD4+CD25+ Tr cells are known to suppress the response of CD4+ T cells in an Ag-nonspecific manner.5,13,19 However, recent studies have shown the Ag-specific suppression of CD4+CD25+ Tr cells in humans and animals.20,21 Analysis of Ag specificity of the inhibitory effect of CD4+CD25+ Tr cells showed that they exhibited both Ag-specific and Ag-nonspecific suppressive effects. These phenomena imply that the heterogeneity of allogeneic regulatory DC-induced CD4+CD25+ Tr cells may reflect the requirement of Ag specificity for their effector function. In contrast to IFN- The mechanism by which CD4+CD25+ Tr and
CD8+CD28 Consistent with previous reports,5,12,16 our results
indicate that direct cell contact of these Tr cells with Ag-primed CD4+ T cells, but not soluble factors secreted from these
Tr cells, appears to be essential for their suppressive capacity. Our
results imply that the suppressive effect of these Tr cells may not be due to simple competition for APCs or IL-2.
CD4+CD25+ Tr cells reportedly blocked the
induction of IL-2 production by CD4+CD25 We showed that hu-PBL-SCID mice succumbed to XGVHD, and the transplanted human T cells obtained from hu-PBL-SCID mice responded to murine normal DCs. Therefore, this xenogeneic response is likely to be mediated through a direct recognition of murine H-2d MHC molecule of SCID mice by human T cells. Furthermore, in vitro priming with murine normal DCs not only enhanced xenogeneic response of human T cells to murine normal DCs but also promoted the lethality caused by XGVHD. These findings suggest that the priming with murine normal DCs up-regulates the ability of human T cells to cause a xenoreactive response. In vitro priming with murine regulatory DCs impaired the ability of human T cells to respond to further stimulation with murine normal DCs as well as to induce XGVHD in hu-PBL-SCID mice. Analysis of SCID mice transplanted with the primed human T cells with murine regulatory DCs revealed that the transplanted human T cells retained an anergic state in vivo. In addition, a single injection with murine regulatory DCs following xenogeneic transplantation caused the therapeutic effect on the lethality caused by XGVHD in hu-PBL-SCID. On the other hand, these protected mice showed similar engraftment of human T cells to that of the control group, indicating that their protective effect may not be due to the failure of their engraftment mediated through the rejection/lysis of the human cells. Interestingly, host APCs reportedly play a crucial role in the initiation and progression of allogeneic acute GVHD, and their inactivation led to the prevention of allogeneic acute GVHD in the murine model.23 Indeed, we showed that murine regulatory DCs also showed a protective effect on allogeneic acute GVHD. Therefore, our finding suggests that murine regulatory DCs could induce an anergic state in human xenoreactive T cells and murine alloreactive T cells, and that led to the protection of the recipients from the lethality caused by XGVHD as well as allogeneic acute GVHD. We also observed that in vitro or in vivo treatment with human IL-2 abrogated the protective effect of murine regulatory DCs on XGVHD in hu-PBL-SCID mice, and it is possibly mediated through the restoration of xenoreactivity of the transplanted human T cells. In summary, regulatory DCs were potent regulators for T cell-mediated immunity in vivo and in vitro, and these cells retained their immunoregulatory property even once matured. Therefore, the strategy with self-Ag (peptides or protein)-pulsed autologous or allogeneic/xenogeneic regulatory DCs in humans may be useful for the prevention and the treatment of inflammation, autoimmune diseases, and allogeneic/xenogeneic organ transplantation. To test our hypothesis, preclinical studies with regulatory DCs in animal immunopathogenic models are being conducted in our laboratories.
We thank Dr Kaori Denda-Nagai for helpful advice on the preparation of murine normal DCs and Mai Yamamoto for her excellent assistance.
Submitted September 6, 2002; accepted December 24, 2002.
Prepublished online as Blood First Edition Paper, January 2, 2003; DOI 10.1182/blood-2002-09-2712.
Supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan (13218027), the Naito Foundation, Nagao Memorial Fund, Japan Rheumatism Foundation, and Kodama Memorial Fund Medical Research (K.S.).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Katsuaki Sato, Department of Immunology and Medical Zoology, School of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima City, Kagoshima 890-8520, Japan; e-mail: katsuaki{at}m3.kufm.kagoshima-u.ac.jp.
1. Banchereau J. Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767-811[CrossRef][Medline] [Order article via Infotrieve].
2.
Sato K, Nagayama H, Tadokoro K, Juji T, Takahashi TA.
Extracellular signal-regulated kinase, stress-activated protein kinase/c-Jun N-terminal kinase, and p38mapk are involved in IL-10-mediated selective repression of TNF- 3. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH. Induction of tolerance by IL-10-treated dendritic cells. J Immunol. 1997;159:4772-4780[Abstract]. 4. Sato K, Yamashita N, Matsuyama T. Human peripheral blood monocyte-derived interleukin-10-induced semi-mature dendritic cells induce anergic CD4+ and CD8+ T cells via presentation of the internalized soluble antigen and cross-presentation of the phagocytosed necrotic cellular fragments. Cell Immunol. 2002;215:186-194[CrossRef][Medline] [Order article via Infotrieve].
5.
Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH.
Induction of interleukin 10-producing, nonproliferating CD4+ T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells.
J Exp Med.
2000;192:1213-1222
6.
Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N.
Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells.
J Exp Med.
2001;193:233-238
7.
Roncarolo M-C, Levings MK, Traverari C.
Differentiation of T regulatory cells by immature dendritic cells.
J Exp Med.
2001;193:F5-F9 8. Luz MB, Kukutsch N, Ogilvie ALJ, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 1999;223:77-92[CrossRef][Medline] [Order article via Infotrieve].
9.
Sato K, Kawasaki H, Morimoto C, Yamashita N, Matsuyama T.
An abortive ligand-induced activation of CC chemokine receptor (CCR)1-mediated downstream signaling event and a deficiency of CCR5 expression are associated with the hyporesponsiveness of human naive CD4+ T cells to CLL3 and CCL5.
J Immunol.
2002;168:6263-6272 10. Sandhu JS, Gorczynski R, Shpitz B, Gallinger S, Nguyen H-P, Hozumi N. A human model of xenogeneic graft-versus-host disease in SCID mice engrafted with human peripheral blood lymphocytes. Transplantation. 1995;60:179-184[Medline] [Order article via Infotrieve]. 11. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell. 2000;101:455-458[CrossRef][Medline] [Order article via Infotrieve].
12.
Shevach EM.
Certified professionals: CD25+CD4+ suppressor T cells.
J Exp Med.
2001;193:F41-F45 13. Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol. 2001;2:816-822[CrossRef][Medline] [Order article via Infotrieve].
14.
Ciubotatiu R, Colovai AI, Pennesi G, et al.
Specific suppression of human CD4+ Th cell responses to pig MHC antigens by CD8+CD28
15.
Colovai AI, Ciubotariu R, Liu Z, Cortesini R, Suciu-Foca N.
CD8+CD28 16. Chan CC, Ciubotariu R, Manavalan JS, et al. Tolerization of dendritic cells by TS cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol. 2002;3:237-243[CrossRef][Medline] [Order article via Infotrieve]. 17. Viola A, Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science. 1996;273:104-106[Abstract].
18.
Penna G, Adorini L.
1
19.
Thornton AM, Shevach EM.
CD25+CD4+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production.
J Exp Med.
1998;188:287-296
20.
Hori S, Haury M, Coutinho A, Demengeot J.
Specificity requirements for selection and effector functions of CD25+4+ regulatory T cells in anti-myelin basic protein T cell receptor transgenic mice.
Proc Natl Acad Sci U S A.
2002;99:8213-8218
21.
Woo E, Yeh H, Chu CS, et al.
Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation.
J Immunol.
2002;168:4272-4276 22. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol. 2002;3:135-142[CrossRef][Medline] [Order article via Infotrieve].
23.
Shlomchik WD, Couzens MS, Tang CB, et al.
Prevention of graft versus host disease by inactivation of host antigen-presenting cells.
Science.
1999;285:412-415
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  K. Sato, K. Eizumi, T. Fukaya, S. Fujita, Y. Sato, H. Takagi, M. Yamamoto, N. Yamashita, A. Hijikata, H. Kitamura, et al. Naturally occurring regulatory dendritic cells regulate murine cutaneous chronic graft-versus-host disease Blood, May 7, 2009; 113(19): 4780 - 4789. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Usui, M. Takeuchi, T. Hattori, Y. Okunuki, K. Nagasawa, T. Kezuka, K. Okumura, H. Yagita, H. Akiba, and H. Goto Suppression of Experimental Autoimmune Uveoretinitis by Regulatory Dendritic Cells in Mice Arch Ophthalmol, April 1, 2009; 127(4): 514 - 519. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. R. Guerin, J. R. Prins, and S. A. Robertson Regulatory T-cells and immune tolerance in pregnancy: a new target for infertility treatment? Hum. Reprod. Update, March 11, 2009; (2009) dmp004v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Zhang, R. Liu, D. Shi, X. Liu, Y. Chen, X. Dou, X. Zhu, C. Lu, W. Liang, L. Liao, et al. Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population Blood, January 1, 2009; 113(1): 46 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Hauben, S. Gregori, E. Draghici, B. Migliavacca, S. Olivieri, M. Woisetschlager, and M. G. Roncarolo Activation of the aryl hydrocarbon receptor promotes allograft-specific tolerance through direct and dendritic cell-mediated effects on regulatory T cells Blood, August 15, 2008; 112(4): 1214 - 1222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Anderson, B. L. Sayers, M. A. Haniffa, D. J. Swan, J. Diboll, X.-N. Wang, J. D. Isaacs, and C. M. U. Hilkens Differential regulation of naive and memory CD4+ T cells by alternatively activated dendritic cells J. Leukoc. Biol., July 1, 2008; 84(1): 124 - 133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Wan, M. A. Versnel, L. M. E. Leijten, C. G. van Helden-Meeuwsen, D. Fekkes, P. J. M. Leenen, N. A. Khan, R. Benner, and R. C. M. Kiekens Chorionic gonadotropin induces dendritic cells to express a tolerogenic phenotype J. Leukoc. Biol., April 1, 2008; 83(4): 894 - 901. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-P. Li, S. Paczesny, E. Lauret, S. Poirault, P. Bordigoni, F. Mekhloufi, O. Hequet, Y. Bertrand, J.-P. Ou-Yang, J.-F. Stoltz, et al. Human Mesenchymal Stem Cells License Adult CD34+ Hemopoietic Progenitor Cells to Differentiate into Regulatory Dendritic Cells through Activation of the Notch Pathway J. Immunol., February 1, 2008; 180(3): 1598 - 1608. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Cools, P. Ponsaerts, V. F. I. Van Tendeloo, and Z. N. Berneman Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells J. Leukoc. Biol., December 1, 2007; 82(6): 1365 - 1374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gerstmayr, N. Ilk, I. Schabussova, B. Jahn-Schmid, E. M. Egelseer, U. B. Sleytr, C. Ebner, and B. Bohle A Novel Approach to Specific Allergy Treatment: The Recombinant Allergen-S-Layer Fusion Protein rSbsC-Bet v 1 Matures Dendritic Cells That Prime Th0/Th1 and IL-10-Producing Regulatory T Cells J. Immunol., December 1, 2007; 179(11): 7270 - 7275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Fujita, Y. Sato, K. Sato, K. Eizumi, T. Fukaya, M. Kubo, N. Yamashita, and K. Sato Regulatory dendritic cells protect against cutaneous chronic graft-versus-host disease mediated through CD4+CD25+Foxp3+ regulatory T cells Blood, November 15, 2007; 110(10): 3793 - 3803. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Li, S. Abediankenari, Y.-J. Kim, T. B. Campbell, S. Ito, B. Graham-Evans, S. Cooper, and H. E. Broxmeyer TGF-{beta} combined with M-CSF and IL-4 induces generation of immune inhibitory cord blood dendritic cells capable of enhancing cytokine-induced ex vivo expansion of myeloid progenitors Blood, October 15, 2007; 110(8): 2872 - 2879. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Hubert, N. Jacobs, J.-H. Caberg, J. Boniver, and P. Delvenne The cross-talk between dendritic and regulatory T cells: good or evil? J. Leukoc. Biol., October 1, 2007; 82(4): 781 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Iwamoto, S.-i. Iwai, K. Tsujiyama, C. Kurahashi, K. Takeshita, M. Naoe, A. Masunaga, Y. Ogawa, K. Oguchi, and A. Miyazaki TNF-{alpha} Drives Human CD14+ Monocytes to Differentiate into CD70+ Dendritic Cells Evoking Th1 and Th17 Responses J. Immunol., August 1, 2007; 179(3): 1449 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Hamdi, V. Godot, M.-C. Maillot, M. V. Prejean, N. Cohen, R. Krzysiek, F. M. Lemoine, W. Zou, and D. Emilie Induction of antigen-specific regulatory T lymphocytes by human dendritic cells expressing the glucocorticoid-induced leucine zipper Blood, July 1, 2007; 110(1): 211 - 219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Schmidt-Lucke, A. Aicher, P. Romagnani, B. Gareis, S. Romagnani, A. M. Zeiher, and S. Dimmeler Specific recruitment of CD4+CD25++ regulatory T cells into the allograft in heart transplant recipients Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2425 - H2431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Qian, H. An, Y. Yu, S. Liu, and X. Cao TLR agonists induce regulatory dendritic cells to recruit Th1 cells via preferential IP-10 secretion and inhibit Th1 proliferation Blood, April 15, 2007; 109(8): 3308 - 3315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Uto, X. Wang, K. Sato, M. Haraguchi, T. Akagi, M. Akashi, and M. Baba Targeting of Antigen to Dendritic Cells with Poly({gamma}-Glutamic Acid) Nanoparticles Induces Antigen-Specific Humoral and Cellular Immunity J. Immunol., March 1, 2007; 178(5): 2979 - 2986. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Y. Lan, Z. Wang, G. Raimondi, W. Wu, B. L. Colvin, A. De Creus, and A. W. Thomson "Alternatively Activated" Dendritic Cells Preferentially Secrete IL-10, Expand Foxp3+CD4+ T Cells, and Induce Long-Term Organ Allograft Survival in Combination with CTLA4-Ig J. Immunol., November 1, 2006; 177(9): 5868 - 5877. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yoshino, H. Yamazaki, L. D. Shultz, and S.-I. Hayashi Constant rate of steady-state self-antigen trafficking from skin to regional lymph nodes Int. Immunol., November 1, 2006; 18(11): 1541 - 1548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Wang, Y. Liu, J. Wang, G. Ding, W. Zhang, G. Chen, M. Zhang, S. Zheng, and X. Cao Induction of Allospecific Tolerance by Immature Dendritic Cells Genetically Modified to Express Soluble TNF Receptor J. Immunol., August 15, 2006; 177(4): 2175 - 2185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Tang, Z. Guo, M. Zhang, J. Wang, G. Chen, and X. Cao Endothelial stroma programs hematopoietic stem cells to differentiate into regulatory dendritic cells through IL-10 Blood, August 15, 2006; 108(4): 1189 - 1197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. I. Iruretagoyena, S. E. Sepulveda, J. P. Lezana, M. Hermoso, M. Bronfman, M. A. Gutierrez, S. H. Jacobelli, and A. M. Kalergis Inhibition of Nuclear Factor-{kappa}B Enhances the Capacity of Immature Dendritic Cells to Induce Antigen-Specific Tolerance in Experimental Autoimmune Encephalomyelitis J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 59 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Wing, Z. Fehervari, and S. Sakaguchi Emerging possibilities in the development and function of regulatory T cells Int. Immunol., July 1, 2006; 18(7): 991 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Gonzalez-Rey, A. Chorny, A. Fernandez-Martin, D. Ganea, and M. Delgado Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells Blood, May 1, 2006; 107(9): 3632 - 3638. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Chorny, E. Gonzalez-Rey, A. Fernandez-Martin, D. Ganea, and M. Delgado Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response Blood, May 1, 2006; 107(9): 3787 - 3794. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Fehervari and S. Sakaguchi CD4+ regulatory cells as a potential immunotherapy Phil Trans R Soc B, September 29, 2005; 360(1461): 1647 - 1661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Li, Y.-J. Kim, and H. E. Broxmeyer Macrophage Colony-Stimulating Factor Drives Cord Blood Monocyte Differentiation into IL-10highIL-12absent Dendritic Cells with Tolerogenic Potential J. Immunol., April 15, 2005; 174(8): 4706 - 4717. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Smith, T. Patterson, and M. E. Pauza Transgenic Ly-49A Inhibits Antigen-Driven T Cell Activation and Delays Diabetes J. Immunol., April 1, 2005; 174(7): 3897 - 3905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Sato, T. Nakaoka, N. Yamashita, H. Yagita, H. Kawasaki, C. Morimoto, M. Baba, and T. Matsuyama TRAIL-Transduced Dendritic Cells Protect Mice from Acute Graft-versus-Host Disease and Leukemia Relapse J. Immunol., April 1, 2005; 174(7): 4025 - 4033. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hirata, S. Senju, H. Matsuyoshi, D. Fukuma, Y. Uemura, and Y. Nishimura Prevention of Experimental Autoimmune Encephalomyelitis by Transfer of Embryonic Stem Cell-Derived Dendritic Cells Expressing Myelin Oligodendrocyte Glycoprotein Peptide along with TRAIL or Programmed Death-1 Ligand J. Immunol., February 15, 2005; 174(4): 1888 - 1897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Bella, S. Nicola, I. Timofeeva, M. L. Villa, A. Santoro, and A. C. Berardi Are interleukin-16 and thrombopoietin new tools for the in vitro generation of dendritic cells? Blood, December 15, 2004; 104(13): 4020 - 4028. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Mandrekar, D. Catalano, A. Dolganiuc, K. Kodys, and G. Szabo Inhibition of Myeloid Dendritic Cell Accessory Cell Function and Induction of T Cell Anergy by Alcohol Correlates with Decreased IL-12 Production J. Immunol., September 1, 2004; 173(5): 3398 - 3407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Vigouroux, E. Yvon, E. Biagi, and M. K. Brenner Antigen-induced regulatory T cells Blood, July 1, 2004; 104(1): 26 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Steinberger, O. Majdic, S. V. Derdak, K. Pfistershammer, S. Kirchberger, C. Klauser, G. Zlabinger, W. F. Pickl, J. Stockl, and W. Knapp Molecular Characterization of Human 4Ig-B7-H3, a Member of the B7 Family with Four Ig-Like Domains J. Immunol., February 15, 2004; 172(4): 2352 - 2359. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
1 (TGF-
), human T cells primed with
murine normal DCs (
), human T cells primed with murine regulatory
DCs (
), or human T cells primed with murine regulatory DCs plus
human IL-2 at a T cell/DC ratio of 10:1 for 3 days (
). Mice were
monitored daily for survival. The results are representative of 2 individual experiments with similar results. P < .01
compared with hu-PBL-SCID mice by the Mann-Whitney U test).
(C) Human T cells were obtained from the spleen in each group of
hu-PBL-SCID mice on day 10 after xenogeneic transplantation. Isolated
human T cells (105) were cultured with murine normal DCs
(103 to 5 × 104), and the proliferative
response was measured on day 5. Data were expressed as mean values ± SDs of 5 individual experiments. *P < .01 compared
with human T cells plus murine normal DCs by Student paired
t test. (D) The hu-PBL-SCID mice were injected with or
without murine regulatory DCs (4 × 106/mouse) 2 days
following xenogeneic transplantation. Alternatively, intravenous
injections of human IL-2 (104U/mouse) were performed on
days 3, 5, and 7 following xenogeneic transplantation in hu-PBL-SCID
mice receiving murine regulatory DCs. Mice were monitored daily
for survival. The results are representative of 2 individual
experiments with similar results. P < .01 compared with
hu-PBL-SCID mice by the Mann-Whitney U test. (E) SCID mice
received transplants of murine allogeneic BM cells plus spleen
mononuclear cells. Subsequently, the recipients were injected with or
without murine normal or regulatory DCs (4 × 106/mouse)
2 days following allogeneic transplantation. Mice were monitored daily
for survival. The results are representative of 2 individual
experiments with similar results. P < .01 compared with
untreated SCID mice that did not receive transplants by the
Mann-Whitney U test.